Trials / Completed
CompletedNCT00857779
Study on Pharmacodynamic Parameter and Tolerability With Subcutaneous Immunotherapy in Grass Pollen Allergic Patients
A Multicentre Randomised Phase II Clinical Trial to Demonstrate Equivalent Pharmacodynamic Efficacy and Tolerability of Two Updosing Schedules for ALK-Flex SQ
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 473 (actual)
- Sponsor
- ALK-Abelló A/S · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to test the pharmacodynamic equivalence with respect to IgE-blocking factor and to compare the tolerability of two different updosing schedules with ALK-Flex SQ
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | subcutaneous immunotherapy | 7 injections |
Timeline
- Start date
- 2009-02-01
- Primary completion
- 2009-08-01
- Completion
- 2009-10-01
- First posted
- 2009-03-09
- Last updated
- 2013-02-08
Locations
1 site across 1 country: Germany
Source: ClinicalTrials.gov record NCT00857779. Inclusion in this directory is not an endorsement.